NeuroSense featuring the CFO

“I think that R&D companies like NeuroSense are doing the greatest thing any company can do. Financially, they are taking an enormous risk with a drive to change the world.”  – Or Eisenberg, CFO

I’ve been with NeuroSense for over three years, starting at our Herzliya office, and now working from New Jersey in the US. Throughout my career, I’ve held various financial roles, beginning with publicly traded Israeli companies. Since 2017, I’ve focused on US-listed companies, including NeuroSense.

What makes us at NeuroSense unique is our enthusiasm to bring a drug into the market for the benefit of ALS patients. We do not forget our motivation.

As the Chief Financial Officer at NeuroSense, I oversee the financial operations that are critical to our success. This includes the day-to-day tasks like managing payments, budgets, cash flow, and financial reporting, as well as ensuring compliance with local authorities and the Securities and Exchange Commission (SEC). My role also extends to fundraising and corporate governance, both of which are essential for driving our mission forward based on the right financial strategy.

To build a solid budget, I collaborate with each department, asking them to forecast their projects and associated costs for the upcoming year. Once I receive their plans, I aggregate the data to assess our financial needs and determine the best strategy to secure the necessary funds. My responsibility is not just to ensure that we have the resources, but also to prioritize activities that will most effectively advance our clinical studies and bring us closer to achieving our goals.

As an R&D company, our funding primarily comes from investors, which makes it crucial to keep them engaged, especially as a publicly traded company, during periods between major news releases. One of the most important aspects of my role is to sustain this interest and excitement. This involves continuously sharing new findings, building and nurturing relationships with both current and potential investors, and keeping the momentum alive. By doing so, we not only maintain their confidence, but also generate the high trading volume that can attract further investment. It’s about creating a lasting buzz that drives our mission forward.

I think that R&D companies like NeuroSense are doing the greatest thing any company can do. Financially, they are taking an enormous risk with a drive to change the world. It is a constant fight to get more investments to fund our work, whereas big pharma companies already have revenue. Still, it is worth it if we can make a difference for people struggling with ALS and other neurodegenerative diseases.